ARQT
Arcutis Biotherapeutics, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- May 29 ▲ Gilbert Cisneros bought $1,001 - $15,000, last disclosed Jun 9
- Jun 15 to Jun 17 ▼ 2 days of insider sells: $236.9K by 2 insiders, avg $24.48
- Jul 15 ▼ 1 insider sell $127.3K at $26.91
- Aug 3 ▼ 3 insiders sell $171.3K at $26.12
- Aug 11 to Aug 27 ▼ 6 days of insider sells: $1.5M by 3 insiders, avg $25.51
- Sep 8 to Sep 16 ▼ 3 days of insider sells: $456.2K by 2 insiders, avg $24.80
- Sep 29 Contract: Simone Biles Partners with Arcutis to Launch the Skin to B…
- Oct 15 Cantor Fitzgerald initiates
- Oct 15 ▼ 1 insider sell $127.3K at $26.93
- Nov 2 to Nov 4 ▼ 2 days of insider sells: $1.6M by 3 insiders, avg $33.97
- Nov 4 Arcutis reported Q3 2026 ZORYVE net product revenue of $143.9M, beat…
- Nov 13 FDA: Arcutis Presents New Caregiver-Reported Outcomes Data Supp…
Signal stack
Where each data set points today.
- InsidersBEARISH
6 insiders sold $4.2M.
- InstitutionsBULLISH
Q3 2026: 39 added (1 new), 8 trimmed or exited. Largest new: Public Sector Pension Investment Board $20.3M.
- AnalystsBULLISH
12 of 14 rate it Buy or better. Every target is above the price.
- EstimatesFALLING
Current-quarter EPS estimate $0.228 → $0.197 over 90 days. 0 up, 1 down in 30 days.
- Short sellersSTEADY
Short interest −11.4% to 18.16M shares. 7.6 days to cover, ≈14.4% of shares.
- TrendUPTREND
3% above its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| BlackRock, Inc. | ADD | $506.7M |
| STATE STREET CORP | ADD | $204.0M |
| UBS Group AG | ADD | $146.2M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | ADD | $100.9M |
| PRINCIPAL FINANCIAL GROUP INC | DOUBLED | $21.2M |
| Squarepoint Ops LLC | ADD | $20.5M |
| PUBLIC SECTOR PENSION INVESTMENT BOARD | NEW | $20.3M |
| JUPITER ASSET MANAGEMENT LTD | DOUBLED | $18.8M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
14 analystsPrice is below the lowest target. Median implies +42%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 5, 2026 | TD Cowen MAINTAIN | Buy |
| Oct 19, 2026 | Guggenheim MAINTAIN | Buy |
| Oct 15, 2026 | Cantor Fitzgerald INITIATE | Overweight |
| Aug 6, 2026 | Morgan Stanley MAINTAIN | Overweight |
| Aug 6, 2026 | Guggenheim MAINTAIN | Buy |
| Aug 6, 2026 | Needham MAINTAIN | Buy |
Washington
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Matsuda Masaru EVP, Chief Legal Officer Nov 4, 2026 | EXERCISE | $145.6K |
Matsuda Masaru EVP, Chief Legal Officer Nov 4, 2026 | SELL | $1.4M |
Watanabe Todd See Remarks Nov 2, 2026 | SELL | $139.5K |
Burnett Patrick EVP, Chief Medical Officer Nov 2, 2026 | SELL | $30.0K |
Matsuda Masaru EVP, Chief Legal Officer Nov 2, 2026 | SELL | $38.8K |
SCOTT ROBERT A Director Oct 23, 2026 | AWARD | 2,819 sh |
SCOTT ROBERT A Director Oct 23, 2026 | AWARD | 20,507 sh |
SCOTT ROBERT A Director Oct 23, 2026 | AWARD | 8,663 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | $0.20 | $0.14–$0.31 | -15.0% | $163.1M |
| Next Q | $0.06 | -$0.09–$0.14 | -52.2% | $145.5M |
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | $1.09 | $0.52–$1.84 | -19.5% | $703.0M |
Short side
FINRA· Oct 30, 2026SecBot reports
31 filings · 3 press releases · 1 bullish · 2 bearish · 2 mixed · 26 neutral- NEUTRAL PRESS RELEASENov 13, 2026
Arcutis presented caregiver-reported outcomes from the INTEGUMENT-INFANT trial of ZORYVE cream…
The PDUFA date of February 23, 2027 is the next key catalyst. Approval would expand ZORYVE's label to infants aged 3-24 months, addressing an unmet need. Monitor FDA review and any advisory…
- NEUTRAL SC 13GNov 10, 2026
State Street Corporation filed a Schedule 13G disclosing a 6.1% passive stake in Arcutis…
State Street's 6.1% passive stake is a routine institutional holding. Monitor for any future 13D conversion or significant share changes, but no near-term activist or control implications are…
- NEUTRAL INST-CLUSTERNov 6, 2026
Five institutional buyers accumulated $25.0M in ARQT during Q3 2026, led by Principal Financial…
The cluster shows conviction from asset managers but lacks insider corroboration and is offset by a $200M ATM. Monitor next 10-Q for continued institutional accumulation and whether the ATM is…
- NEUTRAL 3/A, CLUSTER, 3Nov 4, 2026
Robert A. Scott filed an amended Form 3 (3/A) disclosing 17,523 shares of Arcutis Biotherapeutics…
These are standard initial beneficial ownership filings for two insiders. No trading activity or material change to the company's financials. Monitor future Form 4 filings for any open-market…
All ARQT filing & press-release reports (34)
- PRESS-RELEASE reportNov 13, 2026
- SC 13G reportNov 10, 2026
- INST-CLUSTER reportNov 6, 2026
- 3/A, CLUSTER, 3 reportNov 4, 2026
- 144 reportNov 4, 2026
- 424B5 reportNov 4, 2026
- 8-K reportNov 4, 2026
- PRESS-RELEASE reportNov 4, 2026
- 144 reportNov 2, 2026
- 144 reportNov 2, 2026
- 3 reportOct 28, 2026
- 8-K reportOct 28, 2026
- PRESS-RELEASE reportOct 21, 2026
- SC 13G/A reportOct 5, 2026
- PRESS-RELEASE reportSep 29, 2026
- CLUSTER reportSep 18, 2026
- CLUSTER reportSep 17, 2026
- CLUSTER reportAug 24, 2026
- CLUSTER reportAug 21, 2026
- CLUSTER reportAug 19, 2026
- 144 reportAug 11, 2026
- CLUSTER reportAug 5, 2026
- PRESS-RELEASE reportAug 5, 2026
- 144 reportAug 3, 2026
- PRESS-RELEASE reportJun 29, 2026
- CLUSTER reportJun 17, 2026
- 8-K reportJun 9, 2026
- CLUSTER reportMay 4, 2026
- 144 reportMay 11, 2026
- CLUSTER reportMay 1, 2026
- PRESS-RELEASE reportMay 6, 2026
- PRESS-RELEASE reportApr 15, 2026
- CLUSTER reportMar 2, 2026
- CLUSTER reportMar 2, 2026